SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am. J. Psychiatry 1992; 149: 11831188.
  • 2
    Linszen D, Lenior M, De Haan L, Dingemans P, Gersons B. Early intervention, untreated psychosis and the course of early schizophrenia. Br. J. Psychiatry Suppl. 1998; 172: 8489.
  • 3
    McGorry PD, Yung AR, Phillips LJ et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry 2002; 59: 921928.
  • 4
    Guttmacher MS. Phenothiazine treatment in acute schizophrenia; effectiveness: The National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. Arch. Gen. Psychiatry 1964; 10: 246261.
  • 5
    Huq ZU. A trial of low doses of risperidone in the treatment of patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder. J. Clin. Psychopharmacol. 2004; 24: 220224.
  • 6
    Emsley RA. Risperidone in the treatment of first-episode psychotic patients: A double-blind multicenter study. Risperidone Working Group. Schizophr. Bull. 1999; 25: 721729.
  • 7
    Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: A rationale and hypothesis. J. Clin. Psychiatry 1996; 57 (Suppl. 11): 6871.
  • 8
    Norman RM, Malla AK. Duration of untreated psychosis: A critical examination of the concept and its importance. Psychol. Med. 2001; 31: 381400.
  • 9
    Taylor DM. Aripiprazole: A review of its pharmacology and clinical use. Int. J. Clin. Pract. 2003; 57: 4954.
  • 10
    Swainston Harrison T, Perry CM. Aripiprazole: A review of its use in schizophrenia and schizoaffective disorder. Drugs 2004; 64: 17151736.
  • 11
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV, 4th edn. American Psychiatric Association, Washington DC, 1994.
  • 12
    Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987; 13: 261276.
  • 13
    Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. Suppl. 1987; 334: 1100.
  • 14
    Sheitman BB, Lee H, Strous R, Lieberman JA. The evaluation and treatment of first-episode psychosis. Schizophr. Bull. 1997; 23: 653661.
  • 15
    Robinson DG, Woerner MG, Alvir JM et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry 1999; 156: 544549.
  • 16
    Di Lorenzo R, Amoretti A, Forghieri M, Fiorini F, Genedani S, Rigatelli M. Aripiprazole: Effectiveness and safety under naturalistic conditions. Exp. Clin. Psychopharmacol. 2007; 15: 569575.
  • 17
    Christensen AF, Poulsen J, Nielsen CT, Bork B, Christensen A, Christensen M. Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study. Acta Psychiatr. Scand. 2006; 113: 148153.
  • 18
    Kane JM, Carson WH, Saha AR et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 2002; 63: 763771.
  • 19
    Potkin SG, Saha AR, Kujawa MJ et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 2003; 60: 681690.
  • 20
    Bhattacharjee J, El-Sayeh HG. Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database Syst. Rev. 2008; (3): CD006617.
  • 21
    Chan HY, Lin WW, Lin SK et al. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: A randomized trial. J. Clin. Psychiatry 2007; 68: 2936.
  • 22
    Zimbroff D, Warrington L, Loebel A, Yang R, Siu C. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, 4-week study. Int. Clin. Psychopharmacol. 2007; 22: 363370.
  • 23
    Freudenreich O, Holt DJ, Cather C, Goff DC. The evaluation and management of patients with first-episode schizophrenia: A selective, clinical review of diagnosis, treatment, and prognosis. Harv. Rev. Psychiatry 2007; 15: 189211.
  • 24
    Wang PS, Walker AM, Tsuang MT et al. Dopamine antagonists and the development of breast cancer. Arch. Gen. Psychiatry 2002; 59: 11471154.
  • 25
    Abraham G, Paing WW, Kaminski J, Joseph A, Kohegyi E, Josiassen RC. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: A prospective study. Am. J. Psychiatry 2003; 160: 16181620.
  • 26
    Dossenbach M, Hodge A, Anders M et al. Prevalence of sexual dysfunction in patients with schizophrenia: International variation and underestimation. Int. J. Neuropsychopharmacol. 2005; 8: 195201.
  • 27
    Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and management. Drugs 2004; 64: 22912314.
  • 28
    El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst. Rev. 2006; (2): CD004578.
  • 29
    Allison DB, Casey DE. Antipsychotic-induced weight gain: A review of the literature. J. Clin. Psychiatry 2001; 62 (Suppl. 7): 2231.
  • 30
    Lehman AF, Lieberman JA, Dixon LB et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 2004; 161: 156.